<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01970280</url>
  </required_header>
  <id_info>
    <org_study_id>0146-13-MMC</org_study_id>
    <secondary_id>0146-13-MMC</secondary_id>
    <nct_id>NCT01970280</nct_id>
  </id_info>
  <brief_title>Low Molecular Weight Heparin in Prevention of Recurrent Arteriovenous Graft Thrombosis in Chronic Hemodialysis Patients.</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Sidney Ben Chetrit</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meir Hospital, Kfar Saba, Israel</source>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the effect of Enoxaparin (LMWH) on the incidence of AV
      graft thromboses in patients on chronic hemodialysis.

      Primary efficacy end point of the study: to compare the time of onset of a new thrombotic
      event after successful angiography of the AV graft.

      Pprimary safety outcome of the study: frequency of hemorrhage. Design and methods: Following
      a first AV graft thrombosis and successful thrombolysis with angioplasty, patients on chronic
      hemodialysis will be randomized to s.c Enoxaparin (Clexane) 0.5 mg/1kg of body weight per day
      or control group (not on Clexane). Patients will be followed for a year or till next AV graft
      thrombotic occlusion, if it occurs before. In both groups we will compare time periods in
      months between first and recurrent thrombotic events of AVG by evaluation the difference
      between two sample means. Also interim analysis of AV grafts patency between the two groups
      will be evaluated at different time points: three, six and twelve months after randomization.
      Patients in both groups will receive unfractionated heparin during dialysis session to
      prevent thrombosis of extracorporeal circulation. Patients from Enoxaparin group will receive
      a half dose (500 units/hour) to prevent possible risk of bleeding during the session. Before
      randomization all patients will be evaluated for hypercoagulability state which will include:
      Factor V Laden deficiency, Anti phospholipid antibodies (APLA), Antithrombin III deficiency
      and Protein C/S deficiency.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the time of onset of a new thrombotic event after successful angiography of the AV graft.</measure>
    <time_frame>1 y</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Hemodialysis Patients</condition>
  <arm_group>
    <arm_group_label>Enoxaparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Following a first AV graft thrombosis and successful thrombolysis with angioplasty, patients on chronic hemodialysis will be randomized to s.c Enoxaparin (Clexane) 0.5 mg/1kg of body weight per day or control group (not on Clexane).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <arm_group_label>Enoxaparin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  hemodialysis patients ≥ 18 years of age after occurrence of AVG thrombosis and
             successful thrombolysis/thrombectomy with angioplasty.

        Exclusion Criteria:

          1. Known allergy to enoxaparin

          2. Persistent systolic blood pressure 180 or more and/or persistent diastolic blood
             pressure 100 or more

          3. Chronic Warfarin treatment

          4. Double antiagregant treatment (aspirin plus clopidogrel)

          5. Platelets count below 80000/µl

          6. Known HIT (Heparin Induced Thrombocytopenia)

          7. Recent bleeding (&lt;2 weeks)

          8. Recent stroke (&lt;4 weeks)

          9. Reduced mental status and inability to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ilan Rozenberg, MD</last_name>
    <phone>+97297471734</phone>
    <email>ilan.rozenberg@clalit.org.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Nephrology and Hypertension, Meir Medical Center</name>
      <address>
        <city>Kfar Sava</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+972-9-7471588</phone>
    </contact>
    <investigator>
      <last_name>Sudney BenChetrit, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helsinki committee</name>
      <address>
        <city>Kfar Sava</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+972-9-7471588</phone>
    </contact>
    <investigator>
      <last_name>Sidney BenChetrit, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2013</study_first_submitted>
  <study_first_submitted_qc>October 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2013</study_first_posted>
  <last_update_submitted>October 25, 2013</last_update_submitted>
  <last_update_submitted_qc>October 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Meir Hospital, Kfar Saba, Israel</investigator_affiliation>
    <investigator_full_name>Dr. Sidney Ben Chetrit</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

